Clinical Trials Directory

Trials / Completed

CompletedNCT01366378

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

A Phase 1, Open-Label, Study of the Effect of Cimetidine, a Known Inhibitor of Active Renal Secretion, on the Single-Dose Pharmacokinetics of Intravenously-Administered Methylnaltrexone in Healthy Adults

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Bausch Health Americas, Inc. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

This open-label study assesses the single-dose pharmacokinetics of intravenously-administered MNTX in healthy adult male and female subjects in the absence of, and in the presence of, orally-administered cimetidine.

Conditions

Interventions

TypeNameDescription
DRUGmethylnaltrexone

Timeline

Start date
2007-01-01
Primary completion
2007-02-01
Completion
2007-02-01
First posted
2011-06-06
Last updated
2019-11-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01366378. Inclusion in this directory is not an endorsement.

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX (NCT01366378) · Clinical Trials Directory